Moderna becomes the latest coronavirus vaccine player to act on the need for a major manufacturing push.
Chiasma hopes to be able to file its oral acromegaly therapy by year-end, and Novartis wants to shore up its MS franchise.
The high doses of recently studied gene therapies threaten manufacturing problems that few have fully considered.